Services

Globally Integrated Preclinical Services

Bridge develops safe and ground breaking new medicines for the pharmaceutical and biotechnology industries through our globally integrated preclinical contract research laboratories in the US and China.  Bridge strives for excellence by providing our clients with studies of sound science, technical proficiency, quality assurance, integrity, and speed of process. 

Preclinical Services Portfolio

Bridge helps clients plan and conduct safety assessment studies to assist compound development programs involving small molecules, biologics, neutraceuticals, vaccines, chemicals, and intermediates.  We conduct short and long-term in vivo studies, from acute to carcinogenicity protocols. 

• General toxicology

• Developmental and Reproductive Toxicology (DART)

• Safety pharmacology (CV, CNS, respiratory)

• Vaccine development

• Pathology services

• Bioanalytical services

• DMPK

Species

• Mice

• Rats

• Rabbits

• Guinea pigs

• Canines

• Non-human primates

• Minipigs

Routes of Administration

• Continuous infusion

• Dermal

• Ocular

• Oral (gavage, capsule, diet, drinking water, etc.)

• Parenteral (I.V., I.M., S.C., I.P., etc.)

• Vaginal and rectal

• Customized

Service and Facilities in the US

Bridge prides itself in all aspects of our GLP-compliant services.  In the Gaithersburg, Maryland facilities, we conduct preclinical studies of all sizes and degrees of complexity in our 90,000 square feet of laboratory and support space.  Bridge’s Maryland facilities are AAALAC International accredited, USDA registered, and we have OLAW assurance as well as DEA and radiation licenses.  Our updated vivariums include state-of-the-art teratology, neurobehavioral, and surgery suites.  Data is collected online using the Provantis™ automated data collection system.

Globally Cost-Effective Service in China

Our China capabilities include most aspects of preclinical discovery and development services.  Bridge has one of the largest and most sophisticated animal vivariums in China.  This facility was designed from the ground up to be operated as AAALAC and US-level GLP compliant.  Bridge employees are extensively trained and certified in a variety of programs involving US-level quality assurance, and technical training.  Bridge employs state-of the-art encryption and other data security methods to protect intellectual property.  Animals are exclusively supplied from US-franchised animal breeders, the only two in China.  This provides the confidence of genetic homogeneity to animal models used in the US and Europe.

First of Its Kind in Asia

Bridge is the first Asian preclinical CRO with western-level attention to detail worthy of any state-of-the-art facility, including

• AAALAC

• Strict data security

• Quality animal supply

• Meticulous US-directed QAU training and compliance

• English SOPs

• Data acquisition using Provantis™

• The capabilities of US board-certified Pathologists and Toxicologists

• A motivated staff possessing excellent English speaking and writing skills. 

Now You Have a Choice

We are the first CRO to provide you with a choice of US or Asia-based drug development services.  Both Bridge sites are globally integrated:

• Equivalent SOPs (English only)

• The same validated data acquisition software (Provantis™)

• Integrated program management and report writing

• Toxicologists and US board-certified pathologists

• Global accreditations

• Animal welfare procedures

• Strict confidentiality and data security

• The industry’s top technical training and certification program. 

Our 15 years of experience, combined with technical proficiency, speed, and regulatory expertise; ensure that you receive quality and timely information in support of your regulatory submissions.  Never before have you been offered the same high-quality services, at competitive prices from a choice of sites in the US and Asia.